Moreover, the mouse model used in the present study, namely Myrcludex B-treated OatpKO mice (briefly referred to as Oatp-Ntcp-model) represents a suitable genetic/pharmacological tool to study the specific contribution of BA to systemic complications of cholestatic liver diseases. The gene discussed is SLCO1A2; the disease is Cholestatic liver disease.